<DOC>
	<DOCNO>NCT02061748</DOCNO>
	<brief_summary>This study opportunity Boehringer Ingelheim collaborate Humana conduct comparative safety effectiveness study dabigatran warfarin use real world data Humana 's health plan operation .</brief_summary>
	<brief_title>The Comparative Safety Effectiveness Warfarin Dabigatran Prescribed Non-valvular Atrial Fibrillation Population With Humana Healthcare Coverage</brief_title>
	<detailed_description>Study Design :</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<criteria>Inclusion criterion : Patient must least one inpatient , one physician office visit , one emergency room visit diagnosis AF index date preindex period . Patients must continuously enrol health plan preindex period Patient must prescription dabigatran warfarin Patient must treatment naive oral anticoagulant ( OAC ) use prior first OAC prescription Aged 1889 year index date . The index date define date first OAC prescription Exclusion criterion : Diagnosis hyperthyroidism preindex period , Having claim follow within 3 month prior first diagnosis AF : cardiac surgery , pericarditis , myocarditis , pulmonary embolism . Any patient least one medical claim valvular heart disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>